GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Debt-to-Equity

BerGenBio ASA (OSL:BGBIO) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Debt-to-Equity?

BerGenBio ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. BerGenBio ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. BerGenBio ASA's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr93.32 Mil. BerGenBio ASA's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BerGenBio ASA's Debt-to-Equity or its related term are showing as below:

During the past 9 years, the highest Debt-to-Equity Ratio of BerGenBio ASA was 0.04. The lowest was 0.00. And the median was 0.00.

OSL:BGBIO's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

BerGenBio ASA Debt-to-Equity Historical Data

The historical data trend for BerGenBio ASA's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Debt-to-Equity Chart

BerGenBio ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only - - - - -

BerGenBio ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 - - - -

Competitive Comparison of BerGenBio ASA's Debt-to-Equity

For the Biotechnology subindustry, BerGenBio ASA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BerGenBio ASA's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BerGenBio ASA's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BerGenBio ASA's Debt-to-Equity falls into.



BerGenBio ASA Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BerGenBio ASA's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

BerGenBio ASA's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BerGenBio ASA  (OSL:BGBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


BerGenBio ASA Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


BerGenBio ASA (OSL:BGBIO) Business Description

Traded in Other Exchanges
Address
Mollendalsbakken 9, Bergen, NOR, 5009
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (OSL:BGBIO) Headlines

No Headlines